PARTICIPA

PARTICIPA

viernes, 20 de noviembre de 2020

A living WHO guideline on drugs for covid-19 | The BMJ



https://www.bmj.com/content/370/bmj.m3379

A living WHO guideline on drugs for covid-19

Practice Rapid Recommendations BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 (Published 04 September 2020) Cite this as: BMJ 2020;370:m3379

Visual summary of recommendation


Interventions Population Disease severity Non-severe Severe Critical SpO 2 <90% on room air Respiratory rate >30 in adults Signs of severe respiratory distress Requires life sustaining treatment Acute respiratory distress syndrome Sepsis Septic shock Absence of signs of severe or critical disease This recommendation applies only to people with these characteristics: Patients with confirmed covid-19 Corticosteroids Recommendation against (weak) Recommendation in favour (strong) Remdesivir Recommendation against (weak) Raised respiratory rate in children ≥60 in children <2 months≥50 in children 2-11 months≥40 in children 1-5 years

©

Publicado por en

No hay comentarios:

Publicar un comentario

Danos tu opinion, enriquece el post.

Suscribirse a: Enviar comentarios (Atom)